Two mechanisms in one medication
Like semaglutide, tirzepatide activates the GLP-1 receptor to slow digestion and increase fullness. It also activates the GIP receptor, another gut hormone involved in insulin response and energy balance. Together these effects support appetite control and metabolic health.
What clinical trials showed
In the SURMOUNT-1 trial, adults without diabetes on the highest tirzepatide dose lost an average of roughly 20% of body weight over 72 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide (about 20% vs. 14%).
Trial averages are not promises. Your provider will discuss which option suits your history, tolerance and goals.
Weekly protocol
- One injection per week on a consistent day
- Starting dose increased in steps, typically every four weeks, as tolerated
- In-person check-ins to track progress and side effects
- Nutrition and hydration coaching throughout
Who may not be a candidate
GLP-1-based medications are not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or those who are pregnant or planning pregnancy. Your evaluation covers these questions.